OrphanDrug
OrphanDrug
Pharma Knowledge Base

muscular atrophy-ataxia-retinitis pigmentosa-diabetes mellitus syndrome

MeSH: C538193ORPHA: 25791 Treatment Available

Contents

  1. 1. Overview
  2. 2. Available Treatments
  3. 3. Clinical Presentation
  4. 4. Classification & Codes

Overview

This disorder is characterized by muscular atrophy, ataxia, retinitis pigmentosa, and diabetes mellitus

Available Treatments (1)

DrugFormStatusCountriesLead Time
Insulin glargine
Cold Chain
Subcutaneous injection, 100 units/mL, 300 units/mLFDA Approved113d

Clinical Presentation

Signs and symptoms associated with muscular atrophy-ataxia-retinitis pigmentosa-diabetes mellitus syndrome, sourced from HPO and Orphanet clinical annotations.

AtaxiaMyopathyType II diabetes mellitusAbnormal retinal pigmentation

Classification & Codes

MeSH Code

C538193

Orphanet Code

ORPHA:2579
muscular atrophy-ataxia-retinitis pigmentosa-diabetes mellitus syndrome
MeSHC538193
OrphanetORPHA:2579
Treatments1 drug(s)
Symptoms on record4 signs
Statuspublished

Treatment Summary

Insulin glargine
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO